Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Scientists Decode How Coronavirus Evades Host Cell Defense

By HospiMedica International staff writers
Posted on 20 Jul 2020
Scientists have determined how the pandemic coronavirus SARS-CoV-2 inhibits the synthesis of proteins in infected cells and shown that it effectively disarms the body’s innate immune system.

Although its name is relatively unspecific and indeed opaque, the Nonstructural Protein 1 (Nsp1) encoded by the coronavirus SARS-Cov-2, which is responsible for the current pandemic, has now been shown to have a devastating effect on host cells. More...
Nsp1 is in fact one of the central weapons used by the virus to ensure its own replication and propagation in human hosts. Nsp1 was identified as a virulence factor following the outbreak of the related SARS coronavirus nearly 20 years ago, when it was shown to inhibit protein synthesis in infected cells. Now scientists from Ludwig Maximilian University (Munich, Germany) and University Hospital of Ulm (Ulm, Germany) have discovered what makes Nsp1 so potent and have describe the protein’s mode of action in detail in their paper.

In all biological cells, the task of synthesizing proteins is performed by complex molecular machines known as ribosomes. Ribosomes interact with messenger RNAs (mRNAs), which serve as blueprints for protein synthesis, and translate the nucleotide sequence of each mRNA into the amino-acid sequence of the corresponding protein. The amino-acid sequence in turn determines the shape and biological function of each individual protein. Ribosomes consist of two distinct subunits, and Nsp1 binds to the smaller one-the 40S subunit. The mRNA initially binds to the small subunit, prior to the latter’s interaction with the 60S subunit to form the cavity through which the mRNA is then threaded. The new study shows that one end of the Nsp1 protein interacts with the 40S subunit in such a way that it prevents binding of the mRNA. With the aid of high-resolution cryo-electron microscopy, the scientists have shown in three-dimensional detail how Nsp1 binds tightly to a specific pocket in the small ribosomal subunit and inhibits the formation of functional ribosomes. Further experiments revealed that Nsp1 can also interact with specific configurational states of the fully assembled ribosome.

In addition, the scientists were able to show that the shutdown of protein synthesis leads to an almost complete collapse of one of the body’s major lines of defense against the virus. Nsp1 inactivates the innate immune response by inhibiting a vital signaling cascade. The scientists hope that the insights gained will make it possible to find ways to neutralize the novel coronavirus, and thus mitigate the severity of the respiratory disease that it causes. One potential approach, they say, would be to develop a molecule that masks the viral protein’s binding site. This should be feasible, since the Nsp1-binding pocket itself appears not to have an essential role in ribosomal function.

Related Links:
Ludwig Maximilian University
University Hospital of Ulm



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.